Of anticancer drug

The unusual tolyporphin was isolated from the Pacific cyanophyte Tolypothrix nodosa and it has been shown that tolyporphin eliminates the multidrug resistance (MDR) in certain carcinoma sublines thus potentiating the cytotoxicity of anticancer drugs in these cell lines.2... 

A number of anticancer drugs have been developed that specifically target kinases known to be oncogenic. The first drug in this area is imatinib mesylate, which targets... 

Due to their promising activities in preclinical investigations, the first clinical data for these new generations of anticancer drugs are eagerly awaited. 

J. A. Hartley, Selectivity in alkylating agent-DNA interactions, in Molecular Aspects of Anticancer Drug-DNA Interactions Vol. 1 (Eds. S. Neidle, M. Waring), CRC Press, Boca Raton, FL, 1993, 1. 

Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Actal998 1400( 1-3) 173—184. 

Fig. 34 Mouse tumor cells (blue) showing penetration of anticancer drug after 24 h. Cancer cells have taken up a chimeric polypeptide-drug combination, shown in magenta. (Adapted from [110])...

Kukowska-Latallo, J.F., Candido, K.A., Cao, Z., Nigavekar, S.S., Majoros, I.J., Thomas, T.P., Balogh, L.P., Khan, M.K., and Baker Jr., J.R. (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65(12), 5317-5324. 

Pt(TV) Prodrugs. Platinum(IV) complexes have been widely studied as potential prodrugs that avoid the limitations of the cisplatin class of anticancer drugs. Indeed, the Pt(IV) compound satraplatin [Pt(cha)Cl2(OAc)2(NH3)] (cha, cyclohexylamine) is currently in clinical trials for treatment of hormone-refractory prostate cancer (Fig. 1) (22). Satraplatin is the first orally bioavailable platinum derivative under active clinical investigation and is particularly attractive because of the convenience of administration, milder toxicity profile, and lack of cross-resistance with cisplatin. These results are promising and support the idea that platinum(IV) complexes offer the opportunity to overcome some of the problems associated with cisplatin and its analogs. 

Grieshaber, C. (1991). Prediction of human toxicity of new antineoplastic drugs from studies in animals. In The Toxicity of Anticancer Drugs. Powis, G. and Hacker, M. Eds. Pergamon Press, New York, pp. 10-24. 

Tsuji A (1998) P-glycoprotein-mediated efflux transport of anticancer drugs at the blood- Van Bree rain barrier. Therap Drug Monitor 20 588-590... 

Breedveld P, Beijnen JH, Schellens JHM (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27 17-24... 

G. M. Dubowchik, K. Mosure, J. O. Knype, R. A. Firestone, Cathepsin B-Sensitive Dipeptide Prodrugs. 2. Models of Anticancer Drugs Pachtaxel, Mitomycin C and Doxorubicin , Bioorg. Med. Chem. Lett. 1998, 8, 3347-3352. 

ASSOCIATION OF ANTICANCER DRUGS WITH DNA AT THE CHROMATIN LEVEL... 

Giloni L, Takeshita M, Johnson F, Iden C, Grollman AP (1981) Bleomycin induced strand-scission of DNA. Mechanism of deoxyribose cleavage. J Biol Chem 256(16) 8608-8615 Gniazdowski M, Czyz M (1999) Transcription factors as targets of anticancer drugs. Acta Biochim Pol 46(2) 255-262... 

---